In that light, as with EPO for red blood cells and G-CSF for neutrophils, IL-7 plays a pivotal role in supporting T cell expansion and function, added Cytheris.
IL-7 was originally discovered by Immunex Corporation (now part of Amgen) and through a process of intellectual property acquisition resulting from several mergers, the compound eventually ended up at what is today sanofi-aventis, from whom Cytheris holds the exclusive worldwide license.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Cytheris SA's corporate website, SEC filings, investor presentations and featured press releases, both from Cytheris SA and industry-specific third party sources, put together by Global Markets Direct's team.
Cytheris SA - Brief Cytheris SA overview including business description, key information and facts, and its locations and subsidiaries.
With these initial results in mind, the real breakthrough for IL-7 therapy lies in the administration of CYT107 shortly after the massive antigen drop triggered by treatment with two HCV DAAs, a drop which usually occurs less than two weeks following the start of antiviral treatment" commented Therese Croughs, MD, Chief Medical Officer of Cytheris.
Currently, Cytheris is conducting multiple international investigations of IL-7 in HIV, HCV, HBV, post-BMT and cancer.
The selection of CYT107 for study in immunotherapy trials conducted by the outstanding investigators from CITN member sites is a clear recognition of the potential of this cytokine to play an important role in the development of new approaches to the treatment of various cancers," said Michel Morre, DVM, President and CEO of Cytheris
Conducted as a collaborative effort of the Centre Leon Berard (the study sponsor), ImmunID Technologies, and Cytheris
, the study, known as ELYPSE-7, is designed to evaluate whether CYT107 treatment is able to correct lymphopenia post-chemotherapy in advanced cancer patients and whether the correction of this lymphopenia by restoration of the immune system will result in a broadening of the repertoire of T cells and a reduction in the risk of severe haematological toxicity, tumor progression and early death.
CD4 T-cell depletion in gut mucosa is an early and key pathogenic event in HIV infection that is associated with T-cell activation1,2," said Michel Morre, DVM, President and CEO of Cytheris
Preclinical studies like the one reported here, that combine a well defined animal model with definitive clinical end points together with a precise elucidation of the immune mechanisms supporting the therapeutic effect, have great prospective value," said Michel Morre, DVM, President and CEO of Cytheris
These results in post-transplant patients are entirely consistent with similar effects observed in our HIV studies, where immunocompromised patients treated with CYT107 show a greatly expanded T cell repertoire that is both functional and long-lasting," said Michel Morre, DVM, President and Chief Executive Officer of Cytheris
The combination of CYT107 with a powerful antiviral agent to treat PML follows the same therapeutic regimen that Cytheris
is investigating in clinical studies of HCV and HBV, where interferon or antiviral therapy is employed to drop the viral load and is then followed by added treatment with CYT107 to clear the virus, a process accompanied by an increase in CD4 and CD8 T cell counts", said Michel Morre, DVM, President and Chief Executive Officer of Cytheris
SA, LG Life Sciences Ltd, Enzo Biochem, Digna Biotech, Daewoong Pharma and IRX Therapeutics.
PARIS -- Cytheris
SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS([R]) - Merck & Co.
PARIS -- Cytheris
SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).